Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Key Highlights
- ➤Ziihera plus tislelizumab and chemotherapy median OS reached 27.0 months
- ➤Ziihera plus tislelizumab and chemotherapy reduced death risk 35% versus trastuzumab regimen
- ➤Ziihera plus chemotherapy median OS 22.9 months, reducing death risk 24%
- ➤Three-year OS reached 39.8% with Ziihera, tislelizumab and chemotherapy
- ➤FDA approved two first-line Ziihera regimens for HER2+ advanced GEA August 25, 2026
Expert Statements
Kohei Shitara, Director of the Department of Gastrointestinal Oncology and principal trial investigator at the National Cancer Center Hospital East
“For patients with HER2+ advanced GEA, long-term survival remains difficult to achieve. With longer follow-up, Ziihera-containing regimens demonstrated a durable overall survival benefit, with nearly 40% of patients treated with Ziihera plus tislelizumab and chemotherapy alive at three years”
Kohei Shitara, Director of the Department of Gastrointestinal Oncology and principal trial investigator at the National Cancer Center Hospital East
“Ziihera plus chemotherapy has also now demonstrated a statistically significant survival benefit over trastuzumab plus chemotherapy. Together, these findings provide strong evidence for Ziihera-containing regimens as the new HER2-directed first-line standard of care.”
Rob Iannone, Executive vice president, global head of R&D, and chief medical officer of Jazz Pharmaceuticals
“These HERIZON-GEA-01 three-year landmark results demonstrate meaningful survival outcomes for patients with HER2+ advanced GEA”
Rob Iannone, Executive vice president, global head of R&D, and chief medical officer of Jazz Pharmaceuticals
“The statistically significant survival benefit observed with Ziihera plus chemotherapy and the durable outcomes seen with Ziihera plus tislelizumab and chemotherapy cement Ziihera as the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA.”
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 PR Newswire
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months
Get started
Create a free account to read the full story.